Welcome to our dedicated page for Design Therapeutics SEC filings (Ticker: DSGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Design Therapeutics, Inc. filings document the regulatory disclosures of a Nasdaq-listed, clinical-stage biotechnology company developing GeneTAC® small-molecule therapies for serious degenerative genetic diseases. Its 8-K reports furnish financial results, corporate presentations, pipeline updates, and material governance events tied to board appointments, resignations, committee assignments, director compensation, and indemnification arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, stockholder voting procedures, and board structure. The filing record also identifies the company’s common stock registration on The Nasdaq Global Select Market, emerging growth company status, and public-company disclosure framework for operations, capital structure, governance, and risk reporting.
Design Therapeutics, Inc. is a clinical-stage biopharma company developing GeneTAC small‑molecule genomic medicines to treat nucleotide repeat expansion diseases by modulating gene transcription at the DNA level. Its lead programs target Friedreich ataxia (FA), Fuchs endothelial corneal dystrophy (FECD), myotonic dystrophy type‑1 (DM1) and Huntington’s disease (HD).
Lead FA candidate DT‑216P2, a reformulation of DT‑216, is in the RESTORE‑FA Phase 1/2 multiple‑ascending dose trial after Phase 1 data showed FXN increases with the prior formulation and improved pharmacokinetics with DT‑216P2. An update on frataxin levels after 12 weeks of dosing is expected in the second half of 2026.
Eye‑drop candidate DT‑168 for FECD has completed a Phase 1 trial in healthy volunteers with favorable safety and is in a Phase 2 biomarker study, with data also expected in the second half of 2026. DM1 candidate DT‑818 has preclinical data showing over 90% toxic RNA foci reduction and has regulatory clearance for a Phase 1 MAD trial, with patient dosing planned in 2026. HD candidates have shown selective mutant huntingtin reduction in patient cells and a mouse model while preserving wild‑type huntingtin.
Design Therapeutics reported higher operating expenses and a wider loss in 2025 as it advanced multiple GeneTAC® programs. Research and development spending was $59.1 million for the year, up from $44.4 million, and net loss increased to $69.8 million from $49.6 million.
Fourth-quarter 2025 net loss was $16.0 million, or $0.27 per share. The company ended 2025 with $219.8 million in cash, cash equivalents and investment securities, which it expects will fund planned operations into 2029.
Clinically, Design continues dosing Friedreich ataxia patients with DT-216P2 and running a Phase 2 biomarker trial of DT-168 in Fuchs endothelial corneal dystrophy, with data from both anticipated in the second half of 2026. It plans to begin dosing myotonic dystrophy type-1 patients with DT-818 in a Phase 1 trial in the first half of 2026, with results expected in 2027, while also progressing preclinical work in Huntington’s disease.
Design Therapeutics, Inc. (DSGN) has a significant shareholder disclosure from Point72-related entities. Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen report beneficial ownership of 5,372,004 shares of common stock, representing 9.4% of the class as of December 31, 2025.
The shares are held by Point72 Associates, an investment fund managed by Point72 Asset Management, which has investment and voting power under an investment management agreement. The reporting persons certify the stake was not acquired to change or influence control of Design Therapeutics.
Design Therapeutics, Inc. reported a governance change, stating that board member Deepa Prasad has decided to resign from the Company’s Board of Directors. Her resignation is effective February 1, 2026 and is attributed to conflict-avoidance policies tied to her newly appointed role with a major bank.
The filing does not describe any disagreement with the Company, instead framing the departure as a compliance requirement related to her new external position. Design Therapeutics remains listed on the Nasdaq Global Select Market under the ticker DSGN, with Pratik Shah continuing as President, Chief Executive Officer and Chairperson.
Design Therapeutics disclosed that its President, CEO and Chairperson, who also serves as a director, holds a stock option to purchase 525,000 shares of common stock at an exercise price of $2.48 per share, originally granted on September 1, 2023.
The option was subject to both time-based vesting and a specific performance condition. On December 9, 2025, the board determined that the performance condition had been met, causing 295,312 of these option shares to vest. The remaining unvested portion is scheduled to vest in equal monthly installments through August 25, 2027, as long as the executive continues to provide service to the company.
Design Therapeutics (DSGN) filed its Q3 10-Q, showing continued investment in its GeneTAC platform and clinical programs. Cash, cash equivalents and investment securities were $206.0 million as of September 30, 2025, and management states resources are sufficient for more than 12 months following issuance. Q3 operating expenses were $19.3 million (research and development $14.6 million; general and administrative $4.7 million), driving a Q3 net loss of $17.0 million. For the nine months, operating expenses totaled $61.3 million and net loss was $53.8 million.
The company is conducting the RESTORE-FA Phase 1/2 MAD trial of DT-216P2 in Friedreich ataxia and anticipates an update on FXN levels in the second half of 2026. In June 2025, the FDA placed a clinical hold on the DT-216P2 IND regarding the starting dose in the United States; the company plans to address the request. In FECD, Phase 2 biomarker data for DT-168 are anticipated in the second half of 2026. A third candidate, DT-818 for DM1, is cleared to begin a Phase 1 MAD trial in Australia in the first half of 2026.
As capital tools, a $300.0 million shelf (including an $100.0 million ATM) became effective in May 2025; no ATM sales occurred as of September 30, 2025. Common shares outstanding were 56,963,757 as of October 31, 2025.
Design Therapeutics, Inc. (DSGN) furnished an 8‑K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1.
The company states this information is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities nor incorporated by reference into other filings. The report was signed by President and CEO Pratik Shah, Ph.D. on November 5, 2025.
Justin D. Gover, a director of Design Therapeutics, Inc. (DSGN), reported two option grants dated 09/09/2025. The filing shows awards of 30,000 and 15,833 stock options with an exercise price of $6.64 each, representing 45,833 underlying shares in total. The reporting form lists these as direct holdings. The filing includes vesting schedules: the 30,000-option award vests in equal monthly installments over 36 months following September 9, 2025, and the 15,833-option award vests in equal monthly installments over 12 months following September 9, 2025. The form was signed on behalf of the reporting person on 09/10/2025.
Design Therapeutics, Inc. reported an initial Form 3 for director Justin D. Gover relating to an event on 09/09/2025. The filing states the reporting person is a Director and that no securities are beneficially owned by Mr. Gover as of the reporting date. The Form 3 was signed by an attorney-in-fact on 09/10/2025. The filing notifies investors that the director currently holds no direct or indirect equity in the issuer.
Design Therapeutics reported a board change effective September 9, 2025. Director Arsani William, M.D. resigned from the board, and the company stated his resignation was not due to any disagreement over operations, policies, or practices.
On the same date, the board appointed Justin Gover as a Class III director with a term running through the 2027 annual meeting of stockholders. He was also named chair of the Compensation Committee. Under the company’s non-employee director compensation policy, he will receive annual cash retainers of $40,000 for board service and $12,000 for serving as Compensation Committee chair, plus stock options to purchase 30,000 shares vesting over three years and a prorated annual option for 15,833 shares vesting over one year.